Advertisement

Role of Central Laboratories in Research, Validation, and Application of Predictive Biomarkers

  • Oliver Stoss
  • Thomas Henkel
Chapter

Abstract

Patient selection for targeted therapies using molecular biomarkers has become mandatory in clinical development and practice in the last 10 years. Consequently, pharmaceutical and companion diagnostics industry needed a reliable and independent partner who is able to validate biomarker assays and apply them reproducibly over many years in a highly standardized manner within a regulatory environment, suited to fulfill the requirements for drug and diagnostic approval. Specialized central laboratories have filled this gap between pharma and diagnostic developers, the CROs who organize clinical trials and the clinical sites, deciding which patient shall be treated with a new experimental therapy. The major contribution of these specialty central labs is the application of a new biomarker test in a highly standardized manner, keeping the variation in sample preparation, test platform, material and devices, test performance, and test interpretation at a minimum.

Keywords

Central lab IVD development Biomarker Validation Clinical trial 

References

  1. 1.
    Scheel AH, Dietel M, Heukamp LC, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;29:1165–72.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637–50.CrossRefGoogle Scholar
  3. 3.
    Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.CrossRefPubMedGoogle Scholar
  4. 4.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687–97.CrossRefGoogle Scholar
  5. 5.
    Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Rüschoff J, Lebeau A., Kreipe H. et al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Mod Pathol. 2017;30(2):217–26.CrossRefPubMedGoogle Scholar
  7. 7.
    U.S. Food & Drug Administration (FDA). Clinical Laboratory Improvement Amendments (CLIA). 2014. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105.htm
  8. 8.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for industry: bioanalytical method validation. May 2001. http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf
  9. 9.
    European Medicines Agency (Science Medicines Health). Guideline on bioanalytical method validation. July 21, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf
  10. 10.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology. 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Targos Molecular Pathology GmbHKasselGermany

Personalised recommendations